SIStockInvestingSI.com

NYSE · CVS · Healthcare Plans

CVS Health (CVS) stock analysis

$93.45−1.37%Data as of Oct 21, 2026
  • CVS gained 7.3% over the past month versus 0.0% for the S&P 500, ranking 113th of 497 S&P 500 stocks.
  • Over 12 months it returned +16.2%, 0.4 points ahead of the S&P 500, and trades 15.0% below its 52-week high.
  • In the last 30 days 4 analysts raised earnings estimates and 2 cut; forward EPS moved +0.1% (+1.5% over 90 days).
  • It sits in the PBMs & pharmacies segment of the Healthcare Value Chain, where the 1-month median return is +9.3%.
  • The daily chart reads Trend transition · Trend repair (since Oct 19, 2026).
Market cap$119.5B
12-month return+16.2%
Forward P/E11.0×
Mean target vs price+23.6%

One-year price with 50- and 200-day averages

Open in Hub
69.381.994.4107JanAprJulOct
93.4550-day200-day

Performance vs the market

Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.

CVS+7.3%
Sector median−8.7%
S&P 5000.0%
CVS−12.6%
Sector median−5.4%
S&P 500+4.7%
CVS+23.3%
Sector median−1.5%
S&P 500+8.7%
CVS+16.2%
Sector median+1.7%
S&P 500+15.8%
1-month rank in the S&P 500113 / 497
3-month rank in its sector · Healthcare428 / 720

Chart structure

Read by our daily-bar structure engine from swing highs, swing lows and moving averages.

Trend transition · Trend repairAwaiting confirmation

Holding since Oct 19, 2026

  • Price and averages have mixed alignment
  • EMA50 fell over the last ten sessions
  • Neither a stable trend nor a range is confirmed
This pattern on this stock

60 occurrences in 10 years. The median move over the next 20 sessions was 0.0%, positive 50% of the time, against +0.2% for any day in the same period.

Reference zone, stop and targets for this structureSee the trade plan in Hub ↗

Analyst earnings revisions

Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.

Forward EPS$8.54
30-day change+0.1%
90-day change+1.5%
Mean target$115.48 +23.6%
Raised (30d) 4Cut (30d) 2

25 analysts cover the stock

Fundamental shape vs peers

Six dimensions on fixed scales. The filled shape is the company; the outline is the peer average.

Open the full Radar with every ratio
ValuationRevisionsMomentumGrowthCashProfit

Ahead of peersGrowth, Valuation

Behind peersMomentum, Profit

PeersUNH · ELV · CI · HUM

Where it sits in the supply chain

Healthcare Value Chain · Distribution & PBMs

Explore the full chain map in Hub
Supplied by
Drug distribution+13.9%
MCK+13.9%1 monthCOR+8.3%1 monthCAH+16.2%1 month
Diagnostics, monitoring & imaging−3.1%
ABT−3.1%1 monthDXCM−10.4%1 monthGEHC+4.1%1 month
Its segment
PBMs & pharmacies+9.3%
CVS+7.3%1 monthCI+11.2%1 monthUNH+11.8%1 month6618.HK+7.3%1 month

Pharmacy benefit managers negotiate drug prices and manage formularies for insurers and employers, and face regulatory reform pressure.

Sells into
Health insurers+11.2%
UNH+11.8%1 monthELV+7.9%1 monthCI+11.2%1 monthCVS+7.3%1 monthHUM+14.4%1 month

Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps

Risk profile

Max drawdown, 12M−22.6%
Volatility, 60D27.8%
From 52-week high−15.0%
From 52-week low+34.5%
Trailing P/E24.7×
Forward P/E11.0×
CICignaUNHUnitedHealth GroupMCKMcKessonCORCencora, Inc.CAHCardinal Health, Inc.ABTAbbott LaboratoriesDXCMDexCom, Inc.ELVElevance Health

Track this stock every day

Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.

Open in Hub ↗